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Xpert MTB/RIF: a game changer for the diagnosis of 
pulmonary tuberculosis in children?
The diagnosis of pulmonary tuberculosis in young 
children is challenging because clinical and radiological 
features are often non-speciﬁ c.1 Achieving a deﬁ nite 
diagnosis through microbiological conﬁ rmation is 
especially problematic in this population owing to 
the typically low bacillary burden and the diﬃ  culty in 
obtaining a quality respiratory specimen. For adults, 
WHO has endorsed a single Xpert MTB/RIF assay for 
initial diagnosis, especially in people with HIV and in 
those with suspected drug-resistant tuberculosis.2 A 
consensus has not yet been reached on the value of the 
Xpert MTB/RIF assay for the diagnosis of pulmonary 
tuberculosis in young children. Xpert MTB/RIF has been 
shown to give a rapid diagnosis on induced sputum,3,4 
nasopharyngeal aspirate,5 and gastric aspirate6 samples 
in about 70% of children in hospital with culture-
conﬁ rmed tuberculosis. Most children with suspected 
tuberculosis, however, present to primary care clinics 
with less severe disease. 
In this context, in The Lancet Global Health, Heather 
Zar and colleagues report ﬁ ndings from the ﬁ rst study 
to assess the accuracy of Xpert MTB/RIF in young 
children presenting to a primary-care facility with 
symptoms of pulmonary tuberculosis.7 Primary analysis 
was done in 309 children in whom four samples (two 
induced sputum samples and two nasopharyngeal 
aspirates) could be collected. On the ﬁ rst induced 
sputum sample, Xpert MTB/RIF assay detected 
12 of 28 culture-conﬁ rmed cases, and on the ﬁ rst 
nasopharyngeal aspirate sample, it detected eight of 
28 culture-conﬁ rmed cases. Tests on repeat samples 
improved the sensitivity of Xpert MTB/RIF to 16 of 
28 culture-conﬁ rmed cases on two induced sputum 
samples and 11 of 28 culture-conﬁ rmed cases on two 
nasopharyngeal aspirate samples. On the basis of these 
results, the investigators suggest that Xpert MTB/RIF 
on two specimens should be recommended in children 
with suspected tuberculosis. At an estimated cost of 
US$26·5 per assay in South Africa (excluding the costs 
of biospecimen collection),8 two Xpert MTB/RIF assay 
on induced sputum samples would have diagnosed 
16 cases of pulmonary tuberculosis at a cost of $1025 
per patient diagnosed. Doing Xpert MTB/RIF on two 
nasopharyngeal aspirate samples, which might be 
more feasible in most resource-poor settings because it 
does not require access to electricity or oxygen, would 
have diagnosed 11 cases at a cost of $1491 per person 
diagnosed. 
Whether repeat sampling (induced sputum, 
nasopharyngeal aspirate, or both) should become 
the initial diagnostic for paediatric tuberculosis in 
low-income countries thus becomes an important 
question. Zar and colleagues state that studies of cost 
eﬃ  cacy of repeated specimens in children are needed. 
A decision to endorse this strategy should also be 
guided by the ability of the Xpert MTB/RIF assay to 
aﬀ ect the management of patients. The diagnostic 
thought process usually starts with the generation of 
a diﬀ erential diagnosis, followed by estimation of the 
pre-test probability, performance of a diagnostic test, 
and estimation of a post-test probability. Health-care 
workers generally start treatment when the post-test 
probability exceeds a threshold. When a negative test 
result decreases the post-test probability low enough to 
refute the hypothesis, health-care workers rule out the 
diagnosis and assess the next diagnostic hypothesis.9 In 
Zar and colleagues’ study, tuberculosis treatment was 
started in 180 (47%) of 384 participating children. Of all 
children started on treatment, almost 90% were Xpert-
MTB/RIF-negative, suggesting that the Xpert MTB/RIF 
results did not substantially change health-care workers’ 
pre-test assessment of the probability of children 
having tuberculosis. The possibility that the strategy 
of empirical treatment for paediatric tuberculosis 
will change in the near future is unlikely in view of the 
absence of a reference standard against which new 
diagnostics for paediatric tuberculosis can be reliably 
assessed. 
What reasoning could determine whether one or two 
induced sputum or nasopharyngeal aspirate samples 
are obtained for Xpert MTB/RIF in young children in 
high-burden, low-income countries? Zar and colleagues’ 
included only 31 children with HIV, restricting the 
ability to assess the value of Xpert MTB/RIF stratiﬁ ed 
by HIV status. An alternative to Xpert MTB/RIF for the 
diagnosis of tuberculosis in young children in primary 
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care could be the use of the urine lipoarabinomannan 
assay. Although this assay has been shown to be useful 
in adults with severe immunosuppression,10 no data 
have been published on its performance in children 
with HIV. The most compelling reason might be the 
suspicion of drug-resistant tuberculosis. In such cases, 
rapid knowledge of the presence of rifampicin resistance 
can inform which children should receive extended 
treatment with potentially toxic second-line drugs. 
Despite the crucial need for rapid, accurate, and 
aﬀ ordable diagnostics for pulmonary tuberculosis in 
young children, it seems unlikely that Xpert MTB/RIF 
will be the game changer that high-burden countries are 
desperately waiting for. 
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